Blog
RSS FeedPosted by Michael Wonder on 04 Dec 2022
Anti-viral drug should not be first choice in treating COVID-19
3 December 2022 - The most widely prescribed anti-viral drug in Australia, molnupiravir, should no longer be routinely given for ...
Posted by Michael Wonder on 22 Nov 2022
Libtayo (cemiplimab) approved by the European Commission as the first immunotherapy in second-line recurrent or metastatic cervical cancer irrespective of PD-L1 expression level or tumour histology
22 November 2022 - Approval based on a Phase 3 trial that demonstrated significant survival benefit in patients with recurrent or ...
Posted by Michael Wonder on 22 Nov 2022
Junshi Biosciences announces approval of supplemental application for additional indications of adalimumab injection
22 November 2022 - Shanghai Junshi Biosciences announced today that the supplemental application for additional indications of adalimumab injection (UBP1211) for ...
Posted by Michael Wonder on 22 Nov 2022
argenx announces US FDA acceptance of biologics license application for subcutaneous efgartigimod in generalised myasthenia gravis with priority review
22 November 2022 - PDUFA target action date is 20 March 2023. ...
Posted by Michael Wonder on 22 Nov 2022
NICE recommends Sobi’s Doptelet to treat thrombocytopenia
18 November 2022 - Primary ITP is a rare autoimmune condition characterised by high platelet destruction ...
Posted by Michael Wonder on 22 Nov 2022
Carfilzomib in combination with daratumumab and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma
22 November 2022 - NICE is unable to make a recommendation on the use of carfilzomib in combination with daratumumab and ...
Posted by Michael Wonder on 22 Nov 2022
Tisagenlecleucel for the treatment of patients with follicular lymphoma after two or more therapies
22 November 2022 - NICE is unable to make a recommendation on the use of tisagenlecleucel for the treatment of adults ...
Posted by Michael Wonder on 21 Nov 2022
Kiwi myeloma cancer sufferers don’t have access to daratumumab, a drug available in Australia
21 November 2022 - Kiwi cancer sufferers are being denied a drug that saves lives in other countries, including Australia ...
Posted by Michael Wonder on 21 Nov 2022
TLV subsidises anti-viral treatment of COVID-19 to risk groups
21 November 2022 - Paxlovid, which treats patients who are at risk of becoming seriously ill from COVID-19, will be ...
Posted by Michael Wonder on 21 Nov 2022
Medicare 2.0 - a vision for the future of America’s health insurance plan
21 November 2022 - Medicare is one of the great successes in American social policy. It provides universal health insurance to ...
Posted by Michael Wonder on 21 Nov 2022
TLV subsidises drugs against cystic fibrosis
18 November 2022 - The Dental and Pharmaceutical Benefits Agency, TLV, has decided that the drugs Kaftrio, Kalydeco and Symkevi, ...
Posted by Michael Wonder on 21 Nov 2022
US FDA accepts for priority review the biologics license application for epcoritamab (DuoBody-CD3xCD20) for the treatment of relapsed/refractory large B-cell lymphoma
21 November 2022 - The application is supported by data from EPCORE NHL-1 Phase 1/2 trial evaluating the safety and preliminary ...
Posted by Michael Wonder on 21 Nov 2022
New Quality Innovation Expert Group supports medicine innovation
21 November 2022 - The EMA has established a Quality Innovation Expert Group to support innovative approaches for the development, ...
Posted by Michael Wonder on 21 Nov 2022
Moderna applies to Swissmedic for authorisation of a second bivalent COVID-19 vaccine
18 November 2022 - Application submitted for Spikevax Bivalent Original / Omicron BA.4-5 (mRNA-1273.222) ...
Posted by Michael Wonder on 21 Nov 2022
Adjustment for baseline characteristics in randomised clinical trials
17 November 2022 - The purpose of randomisation in clinical trials is to ensure that there are no systematic differences between ...
Posted by Michael Wonder on 21 Nov 2022
Bristol Myers Squibb warns US price reforms will dent drug development
20 November 2022 - Biggest shake-up in pharma pricing in decades prompts companies to shelve some potential therapies. ...